The tumor mutation burden and PD-L1 expression were not found to be related to MPR in patients with NSCLC treated with neoadjuvant chemotherapy plus anti-PD-1/PD-L1 (CAPD). The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.